The iStent infinite is under evaluation in an investigational device exemption FDA trial as a MIGS device that is performed independent of cataract surgery.
As we know, the original iStent, the iStent inject (both Glaukos) and the Hydrus (Ivantis) were all approved for implantation in patients with mild to moderate glaucoma in conjunction with cataract surgery. In the current trial, the group of patients was much more difficult to control. These patients had uncontrolled IOP on medications, and many had already undergone failed incisional surgery. It was a tough group (Read more...)
Uncategorized